Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
P/E Ratio
--
P/B Ratio
0.04
Industry P/E
--
Debt to Equity
0
ROE
-1.66 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-1.09
CFO
$-251.02 Mln
EBITDA
$-264.40 Mln
Net Profit
$-266.79 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Bellerophon Therapeutics (BLPH)
| -67.57 | -- | -- | -67.57 | -84.45 | -70.83 | -- |
|
BSE Sensex*
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Bellerophon Therapeutics (BLPH)
| -95.89 | -70.97 | -53.52 | 27.16 | -56.36 | -68.74 | 395.96 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide... delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. Read more
President, Treasurer, Secretary, Principal Executive, Financial & Accounting Officer and Director
Mr. Craig R. Jalbert CIRA
President, Treasurer, Secretary, Principal Executive, Financial & Accounting Officer and Director
Mr. Craig R. Jalbert CIRA
Headquarters
Warren, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Bellerophon Therapeutics Inc (BLPH) stood at $ 6 Mln as on 30-Sep-23
The share price of Bellerophon Therapeutics Inc (BLPH) is $0.01 (NASDAQ) as of 18-Dec-2024 12:51 EDT. Bellerophon Therapeutics Inc (BLPH) has given a return of -84.45% in the last 3 years.
Bellerophon Therapeutics Inc (BLPH) has a market capitalisation of $ 0 Mln as on 18-Dec-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Bellerophon Therapeutics Inc (BLPH) is 0.04 times as on 18-Dec-2024, a 98% discount to its peers’ median range of 2.30 times.
Since, TTM earnings of Bellerophon Therapeutics Inc (BLPH) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bellerophon Therapeutics Inc (BLPH) and enter the required number of quantities and click on buy to purchase the shares of Bellerophon Therapeutics Inc (BLPH).
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
The CEO & director of Mr. Craig R. Jalbert CIRA. is Bellerophon Therapeutics Inc (BLPH), and CFO & Sr. VP is Mr. Craig R. Jalbert CIRA.
There is no promoter pledging in Bellerophon Therapeutics Inc (BLPH).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Bellerophon Therapeutics Inc. (BLPH) | Ratios |
|---|---|
|
Return on equity(%)
|
-162.93
|
|
Operating margin(%)
|
-194.45
|
|
Net Margin(%)
|
-204.52
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Bellerophon Therapeutics Inc (BLPH) was $2 Mln.
$-0.04
(
